Difference between revisions of "Moclobemide-maprotiline"

From Psychiatrienet
Jump to: navigation, search
Line 3: Line 3:
 
| to = maprotiline  
 
| to = maprotiline  
 
| stop =  
 
| stop =  
{{stopMoclobemide}}
+
{{generaldecrease25p3d}}
 +
{{24Hwashout}}
 
| start =  
 
| start =  
* '''Day 9:''' start maprotiline in a normal dosage of 25-75 mg/day.
+
{{generalstart}}
  
 
|info=
 
|info=

Revision as of 09:10, 20 June 2016

Moclobemide
Type Antidepressant
Group MAO-I
links
Medscape Moclobemide
PubChem 4235
PubMed Moclobemide
Kompas (Dutch) Moclobemide
Wikipedia Moclobemide
Maprotiline
Type Antidepressant
Group NRI
links
Medscape Maprotiline
PubChem 4011
PubMed Maprotiline
Kompas (Dutch) Maprotiline
Wikipedia Maprotiline

Switch medication from moclobemide to maprotiline.[1] [2]

Nietinrijdenbord.png Stop moclobemide
  • Decrease with about 25% of original dose every 3 days
  • Stop and wait for about 24 hour as a washout period
Eenrichtingbord.png Start maprotiline
  • Start with the initial dose
Infobord.png More information
  • “Start low, go slow” is not required, but caution is necessary.
  • Because of short halve life of moclobemide after stopping, the next antidepressant can start next day.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.